The success of mRNA technology during the COVID-19 pandemic opened new avenues for other vaccines. Dr. Sehulong Robert Moraba took a leading role in this frontier as the Principal Investigator for a Phase 3 study (C4781004) evaluating Moderna’s mRNA-based influenza vaccine.
This randomized, observer-blinded trial compared the efficacy, safety, and immunogenicity of the novel mRNA vaccine against a standard licensed inactivated flu vaccine in healthy adults. Leading this trial (SAHPRA ref: 20230219) at Setshaba Research Centre, Dr. Moraba helped generate critical data on whether mRNA platforms can provide superior or more adaptable protection against seasonal influenza.
